VIDEO: Using @RISK in Evaluating Full (late stage) Compound Development in the Pharmaceutical Industry

This free webcast video, presented by Palisade client Venkat Raman, Managing Principal of VR Advisors, discusses the financial evaluation of late-stage development of compounds in the pharmaceutical industry. However, the rationale, methodology, and analysis discussed here have universal applicability to any multi-stage product development activities across industries. In this webcast, we: Present the case – […]

Making Medicine Count: The DecisionTools Suite Bolsters Efficacy of Humanitarian Programs

Getting life-saving drugs to under-served people in developing countries is a driving goal for many non-profit organizations. However, well-intentioned efforts like these can fall short of their desired impact due to poor understanding of market uncertainty and risks associated with pharmaceutical manufacturing. Linskbridge, SPC, a consulting firm that advises international development organizations in determining what […]

Want To Launch A New Drug? @RISK Can Help

For biotechnology or pharmaceutical firms, development presents a significantly risky prospect. Development times are usually prolonged by step-wise clinical trials, and there is only  a 20% chance that a new drug beginning clinical trials will ever reach the market. Nevertheless, the potential return can reach billions of dollars. For startup companies, it is crucial that […]

Using @RISK for a Drug Development Decision: a Classroom Example

At Illinois State University, Associate Professor of Finance Domingo Joaquin uses @RISK to demonstrate how simulation modeling can be employed to support the R&D decision of a pharmaceutical firm, illustrating countless risk evaluation examples to students. Dr. Joaquin uses the example of the fictitious company “Drugco”, which has just successfully completed Phase I and Phase […]